Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1977 May;39(5):536–539. doi: 10.1136/hrt.39.5.536

Comparison of dobutamine and dopamine in treatment of severe heart failure.

J D Stoner 3rd, J L Bolen, D C Harrison
PMCID: PMC483271  PMID: 324501

Abstract

The haemodynamic effects of dobutamine, a new synthetic catecholamine, were studied in 12 patients with severe congestive heart failure and compared with those of dopamine in 10 clinically similar patients. Dobutamine produced a distinct increase in cardiac index, while lowering left ventricular end-diastolic pressure and leaving mean aortic pressure unchanged. Dopamine also significantly improved cardiac index, but at the expense of a greater increase in heart rate than occurred with dobutamine. Dopamine was ineffective in lowering left ventricular end-diastolic pressure, but increased mean aortic pressure. We conclude that dobutamine is an effective, positive inotropic agent in patients with severe congestive heart failure. Because it has comparatively little effect on heart rate and aortic pressure, both major determinants of myocardial oxygen consumption, it may be of special value in patients with the low output syndrome associated with coronary heart disease.

Full text

PDF
538

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akhtar N., Mikulic E., Cohn J. N., Chaudhry M. H. Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol. 1975 Aug;36(2):202–205. doi: 10.1016/0002-9149(75)90526-3. [DOI] [PubMed] [Google Scholar]
  2. COHN J. N., LURIA M. H. STUDIES IN CLINICAL SHOCK AND HYPOTENSION. II. HEMODYNAMIC EFFECTS OF NOREPINEPHRINE AND ANGIOTENSIN. J Clin Invest. 1965 Sep;44:1494–1504. doi: 10.1172/JCI105256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Elliott W. C., Gorlin R. Isoproterenol in treatment of heart disease. Hemodynamic effects in circulatory failure. JAMA. 1966 Aug 1;197(5):315–320. [PubMed] [Google Scholar]
  4. Goldberg L. I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972 Mar;24(1):1–29. [PubMed] [Google Scholar]
  5. Gunnar R. M., Loeb H. S., Pietras R. J., Tobin J. R., Jr Ineffectiveness of isoproterenol in shock due to acute myocardial infarction. JAMA. 1967 Dec 25;202(13):1124–1128. [PubMed] [Google Scholar]
  6. Gunnar R. M., Loeb H. S. Use of drugs in cardiogenic shock due to acute myocardial infarction. Circulation. 1972 May;45(5):1111–1124. doi: 10.1161/01.cir.45.5.1111. [DOI] [PubMed] [Google Scholar]
  7. Holloway E. L., Polumbo R. A., Harrison D. C. Acute circulatory effects of dopamine in patients with pulmonary hypertension. Br Heart J. 1975 May;37(5):482–485. doi: 10.1136/hrt.37.5.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lipp H., Falicov R. E., Resnekov L., King S. The effects of dopamine on depressed myocardial function following coronary embolization in the closed-chest dog. Am Heart J. 1972 Aug;84(2):208–214. doi: 10.1016/0002-8703(72)90335-3. [DOI] [PubMed] [Google Scholar]
  9. MCNAY J. L., MCDONALD R. H., Jr, GOLDBERG L. I. DIRECT RENAL VASODILATATION PRODUCED BY DOPAMINE IN THE DOG. Circ Res. 1965 Jun;16:510–517. doi: 10.1161/01.res.16.6.510. [DOI] [PubMed] [Google Scholar]
  10. Maroko P. R., Kjekshus J. K., Sobel B. E., Watanabe T., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 Jan;43(1):67–82. doi: 10.1161/01.cir.43.1.67. [DOI] [PubMed] [Google Scholar]
  11. Nash C. W., Wolff S. A., Ferguson B. A. Release of tritiated noradrenaline from perfused rat hearts by sympathomimetic amines. Can J Physiol Pharmacol. 1968 Jan;46(1):35–42. doi: 10.1139/y68-006. [DOI] [PubMed] [Google Scholar]
  12. Robie N. W., Nutter D. O., Moody C., McNay J. L. In vivo analysis of adrenergic receptor activity of dobutamine. Circ Res. 1974 May;34(5):663–671. doi: 10.1161/01.res.34.5.663. [DOI] [PubMed] [Google Scholar]
  13. Smith H. J., Oriol A., Morch J., McGregor M. Hemodynamic studies in cardiogenic shock. Treatment with isoproterenol and metaraminol. Circulation. 1967 Jun;35(6):1084–1091. doi: 10.1161/01.cir.35.6.1084. [DOI] [PubMed] [Google Scholar]
  14. Sonnenblick E. H., Skelton C. L. Myocardial energetics: basic principles and clinical implications. N Engl J Med. 1971 Sep 16;285(12):668–675. doi: 10.1056/NEJM197109162851208. [DOI] [PubMed] [Google Scholar]
  15. Tsai T. H., Langer S. Z., Trendelenburg U. Effects of dopamine and alpha-methyl-dopamine on smooth muscle and on the cardiac pacemaker. J Pharmacol Exp Ther. 1967 May;156(2):310–324. [PubMed] [Google Scholar]
  16. Tuttle R. R., Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185–196. doi: 10.1161/01.res.36.1.185. [DOI] [PubMed] [Google Scholar]
  17. Vatner S. F., Higgins C. B., Braunwald E. Effects of norepinephrine on coronary circulation and left ventricular dynamics in the conscious dog. Circ Res. 1974 Jun;34(6):812–823. doi: 10.1161/01.res.34.6.812. [DOI] [PubMed] [Google Scholar]
  18. Vatner S. F., McRitchie R. J., Braunwald E. Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs. J Clin Invest. 1974 May;53(5):1265–1273. doi: 10.1172/JCI107673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vatner S. F., Millard R. W., Higgins C. B. Coronary and myocardial effects of dopamine in the conscious dog: parasympatholytic augmentation of pressor and inotropic actions. J Pharmacol Exp Ther. 1973 Nov;187(2):280–295. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES